FDA has authorized for use a new test for the diagnosis of H1N1 influenza virus infections. This test was developed by the CDC.
FDA has authorized for use a new test for the diagnosis of H1N1 influenza virus infections. This test was developed by the Centers for Disease Control and Prevention (CDC).
This new test replaces the previous real-time polymerase chain reaction (PCR) diagnostic test that was granted emergency-use authorization by FDA in April 2009. The newly approved PCR panel has been optimized by using all of the available 2009 H1N1 genetic information that CDC received during the outbreak. The test has sensitivity and specificity greater than 96% for upper respiratory specimens.
CDC issues health advisory alert after increases in RSV activity
September 6th 2023Due to increased RSV activity observed in Southeastern regions of the United States, the Centers for Disease Control and Prevention (CDC) has issued an official Health Alert Network Health Advisory. The CDC recommends that clinicians prepare to implement recently FDA-approved prevention methods.
Chikungunya vaccine effective in adolescents after phase 3 trial
August 14th 2023Basis for a Biologics License Application submission to the FDA is being built for PXVX0317, following topline results demonstrated in a pair of phase 3 trials, including 1 trial featuring adolescents and adults aged 12 to 64 years.
2 Clarke Drive
Cranbury, NJ 08512